Lee Hyukjoon, Yoon Chang Jin, Seong Nak Jong, Jeon Chang Ho, Yoon Ho Il, Go Joongseok
Division of Vascular and Interventional Radiology, Department of Radiology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea, 13620.
Division of Vascular and Interventional Radiology, Department of Radiology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea, 13620.
J Vasc Interv Radiol. 2017 Aug;28(8):1161-1166. doi: 10.1016/j.jvir.2017.03.029. Epub 2017 Apr 25.
To describe angiographic findings and assess safety and effectiveness of bronchial artery embolization (BAE) with N-butyl cyanoacrylate (NBCA) in patients with cryptogenic hemoptysis (CH).
Between May 2003 and March 2014, 26 patients who underwent BAE for CH were enrolled. A retrospective review was conducted for angiographic findings and clinical outcomes of BAE, including technical and clinical success, complications, and recurrent hemoptysis.
Selective arteriograms were abnormal in 22 patients (85%), showing hypertrophied bronchial arteries (n = 19), parenchymal hypervascularity (n = 18), and bronchial-to-pulmonary shunting (n = 8). All abnormal bronchial and nonbronchial collateral arteries (n = 36) were successfully embolized with NBCA. Hemoptysis ceased within 24 hours in all patients. There were no procedure-related complications. During 11-117 months of follow-up (median, 60.2 mo), 1 patient (4%) experienced recurrent hemoptysis at 5 months after initial BAE, which was treated with repeat BAE. The 5-year hemoptysis-free survival rate was 96%.
Bronchial arteries were angiographically abnormal in most patients with CH (85%). BAE is a safe and effective treatment with excellent short- and long-term results in patients with CH. NBCA appears to be a useful embolic material for this application.
描述血管造影结果，并评估用氰基丙烯酸正丁酯（NBCA）进行支气管动脉栓塞术（BAE）治疗隐匿性咯血（CH）患者的安全性和有效性。
纳入2003年5月至2014年3月间因CH接受BAE治疗的26例患者。对BAE的血管造影结果和临床结局进行回顾性分析，包括技术和临床成功率、并发症及咯血复发情况。
22例患者（85%）的选择性动脉造影异常，表现为支气管动脉增粗（n = 19）、实质血管增多（n = 18）和支气管-肺分流（n = 8）。所有异常的支气管和非支气管侧支动脉（n = 36）均成功用NBCA栓塞。所有患者咯血均在24小时内停止。无手术相关并发症。在11至117个月的随访期（中位时间为60.2个月）内，1例患者（4%）在首次BAE后5个月出现咯血复发，经再次BAE治疗。5年无咯血生存率为96%。
大多数CH患者（85%）的支气管动脉血管造影异常。BAE是一种安全有效的治疗方法，对CH患者有良好的短期和长期效果。NBCA似乎是用于此用途的一种有用的栓塞材料。
